Bladder cancer risk associated with genotypic polymorphism of the matrix metalloproteinase-1 and 7 in North Indian population

Disease Markers

Volumn 29, Issue 1, 2010, Pages 37-46

  Srivastava, Priyanka ^a   Gangwar, Ruchika ^a   Kapoor, Rakesh ^a   Mittal, Rama D ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Bacillus Calmette Gu rin; bladder cancer; haplotypes; matrix metalloproteinase; polymorphism; recurrence free survival

Indexed keywords

BCG VACCINE; INTERSTITIAL COLLAGENASE; MATRILYSIN;

ADULT; ARTICLE; BLADDER CANCER; CANCER GRADING; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CIGARETTE SMOKING; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENETIC RISK; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; INDIA; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM;

MYCOBACTERIUM BOVIS BCG; NICOTIANA TABACUM;

EID: 77957236220     PISSN: 02780240     EISSN: None     Source Type: Journal    
DOI: 10.3233/DMA-2010-0724     Document Type: Article

References (30)

1. D.M. Parkin, The global burden of urinary bladder cancer, Scand J Urol Nephrol Suppl 218 (2008), 12-20.
2. W.J. Kim and S.C. Bae, Molecular biomarkers in urothelial bladder cancer, Cancer Sci 99 (2008), 646-652. (Pubitemid 351448065)
3. Y. Shintani, Y. Sawada, T. Inagaki et al., Intravesical instillation therapy with bacillus Calmette-Guérin for superficial bladder cancer: study of the mechanism of bacillus Calmette-Guérin immunotherapy, Int J Urol 14 (2007), 140-146. (Pubitemid 46121952)
4. F. Levi, Cancer prevention: epidemiology and perspectives, Eur J Cancer 35 (1999), 1912-1924. (Pubitemid 30026213)
5. A. Tardon, W.J. Lee, M. DelgadoRodriguez et al., Leisuretime physical activity and lung cancer: a metaanalysis, Cancer Causes Control 16 (2005), 389-397. (Pubitemid 40897831)
6. S. Ye, Influence of matrix metalloproteinase genotype on cardiovascular disease susceptibility and outcome, Cardiovasc Res 69 (2006), 636-645. (Pubitemid 43139726)
7. P. Ocharoenrat, P. Leksrisakul and S. Sangruchi, A functional polymorphism in the matrix metalloproteinase1 gene promoter is associated with susceptibility and aggressiveness of head and neck cancer, Int J Cancer 118 (2006), 2548-2553.
8. A.K. Kader, J. Liu, L. Shao et al., Matrix metalloproteinase polymorphisms are associated with bladder cancer invasiveness, Clin Cancer Res 13 (2007), 2614-2620. (Pubitemid 46788027)
9. T. Fujimoto, S. Parry, M. Urbanek, M. Sammel et al., A single nucleotide polymorphism in the matrix metalloproteinase1 (MMP1) promoter influences amnion cellMMP1 expression and risk for preterm premature rupture of the fetal membranes, J Biol Chem 277 (2002), 6296-6302. (Pubitemid 34968421)
10. Z. Cao, C. Li, L. Jin and E.F. Corbet, Association of matrix metalloproteinase1 promoter polymorphism with generalized aggressive periodontitis in a Chinese population, J Periodontal Res 40 (2005), 427-431. (Pubitemid 41673745)
11. H. Hirata, K. Naito, S. Yoshihiro et al., A single nucleotide polymorphism in the matrix metalloproteinase1 promoter is associated with conventional renal cell carcinoma, Int J Cancer 106 (2003), 372-374. (Pubitemid 36870398)
12. F. Zinzindohoué, T. Lecomte, J.M. Ferraz et al., Prognostic significance ofMMP1 andMMP3 functional promoter polymorphisms in colorectal cancer, Clin Cancer Res 11 (2005), 594-599. (Pubitemid 40116884)
13. L. Six, C. Grimm, S. Leodolter et al., A polymorphism in the matrix metalloproteinase1 gene promoter is associated with the prognosis of patients with ovarian cancer, Gynecol Oncol 100 (2006), 506-510. (Pubitemid 43246866)
14. S. Jormsjö, C. Whatling, D.H. Walter et al., Allelespecific regulation of matrix metalloproteinase7 promoter activity is associated with coronary artery luminal dimensions among hypercholesterolemic patients, Arterioscler Thromb Vasc Biol 21 (2001), 1834-1839. (Pubitemid 34219789)
15. J. Zhang, X. Jin, S. Fang et al., The functional polymorphism in thematrixmetalloproteinase7 promoter increases susceptibility to esophageal squamous cell carcinoma, gastric cardiac adenocarcinoma and nonsmall cell lung carcinoma, Carcinogenesis 26 (2005), 1748-1753. (Pubitemid 41487990)
16. M. Colombel,M. Soloway and H.Akaza, Epidemiology, Staging, Grading and risk stratification of bladder cancer, Euro Urol Suppl 7 (2008), 618-626.
17. S.A. Miller, D.D. Dykes and H.F. Polesky, A simple salting out procedure for extractingDNA from human nucleated cells, Nucleic Acids Res 16 (1988), 1215.
18. M. Jurajda, J. Muzík, L. Izakovicová Hollá and J. Vácha, A newly identified single nucleotide polymorphism in the promoter of thematrixmetalloproteinase1 gene, Mol Cell Probes 16 (2002), 63-66. (Pubitemid 34246212)
19. M. Bjorklund and E. Koivunen, Gelatinasemediated migration and invasion of cancer cells, Biochim Biophys Acta 1755(2005), 37-69. (Pubitemid 40720240)
20. W.G. StetlerStevenson, L.A. Liotta and D.E. Kleiner, Extracellular matrix 6: role of matrix metalloproteinases in tumor Invasion and metastasis, FASEB J 7 (1993), 1434-1441. (Pubitemid 24003262)
21. Y. Kanamori,M.Matsushima, T.Minaguchi et al., Correlation between expression of the matrix metalloproteinase1 gene in ovarian cancers and insertion/deletion polymorphism in its promoter region, Cancer Res 5 (1999), 4225-4227. (Pubitemid 29418732)
22. S. Ye, P. Eriksson, A. Hamsten et al., Progression of coronary atherosclerosis is associated with a common genetic variant of the human stromelysin1 promoter which results in reduced gene expression, J Biol Chem 271 (1996), 13055-13060. (Pubitemid 26175880)
23. A.I. Tasci, V. Tugcu, E. Ozbek et al., A singlenucleotide polymorphism in the matrix metalloproteinase1 promoter enhances bladder cancer susceptibility, BJUInt 101 (2008), 503-507. (Pubitemid 351160936)
24. Y. Zhu,M.R. Spitz, L. Lei et al., A single nucleotide polymorphism in the matrix metalloproteinase1 promoter enhances lung cancer susceptibility, Cancer Res 61 (2001), 7825-7829. (Pubitemid 33049371)
25. U.K. SaarialhoKere, E.C. Crouch and W.C. Parks, Matrix metalloproteinase matrilysin is constitutively expressed in adult human exocrine epithelium, J Invest Dermatol 105 (1995), 190-196.
26. W.H.Yu, J.F.Woessner, Jr., J.D.McNeish et al., CD44 anchors the assembly of matrilysin/MMP7 with heparinbinding epidermal growth factor precursor and ErbB4 and regulates female reproductive organ remodeling, Genes Dev 16 (2002), 307-323.
27. G. Ghilardi, M.L. Biondi, M. Erario et al., Colorectal carcinoma susceptibility and metastases are associated with matrix metalloproteinase7 promoter polymorphisms, Clin Chem 49 (2003), 1940-1942. (Pubitemid 37340333)
28. Y. Li, X. Jin, S. Kang et al., Polymorphisms in the promoter regions of the matrix metalloproteinases1, 3, 7, and 9 and the risk of epithelial ovarian cancer in China, Gynecol Oncol 101 (2006), 92-96. (Pubitemid 43303565)
29. C. Yu, K. Pan, D. Xing et al, Correlation between asingle nucleotide polymorphism in the matrix metalloproteinase2 promoter and risk of lung cancer, Cancer Res 62 (2002), 6430-6433. (Pubitemid 35364100)
30. C. Lahmann, J. Bergemann, G. Harrison et al., Matrix metalloproteinase1 and skin ageing in smokers, Lancet 357 (2001), 935-936. (Pubitemid 32247288)